Building iteration into the product commercialization process can help life sciences companies avoid many of the missteps ...

The global DNA sequencing services market is poised for significant expansion, with a projected valuation of USD 945.6 million in 2023, expected to surge to USD 2,080.2 million by 2033, according to ...

PRNewswire/ - NetraMark Holdings Inc. (the "Company" or "NetraMark")  a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the ...

From diving into the ever-evolving landscape of AI in drug development to opening up the conversation to discuss regulatory hurdles and how the industry will overcome them, the Summit has been ...

Developing new drugs to treat illnesses has typically been a slow and expensive process. However, a team of researchers at ...

Welcome to the latest edition of “Quantum Leap” where The Fly decodes news and activity in the quantum computing space. PHOTONIC VIBROMETER ORDER: ...

Braze's strong margin execution in 4Q25, clear customer quality improvements, and the pivot to vertical GTM are all positive signals. Learn more on BRZE stock here.

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Simone Steiner, PhD, as ...

Industries are using AI, Digital PLM and Digital Thread, resulting in a transparent adoption that helps satisfy changing ...

| Project Optimus is changing the landscape of oncology drug development by redefining dose optimization standards. Learn how ...

Research and development expenses were $36.3 million and $40.8 million for the years ended December 31, 2024 and 2023, respectively. The decrease was primarily due to decreases in clinical trial costs ...